| scholarly article | Q13442814 |
| P50 | author | Yuri V Bobryshev | Q88065781 |
| Michael Bukrinsky | Q92173385 | ||
| Anthony M Dart | Q37841500 | ||
| P2093 | author name string | Dmitri Sviridov | |
| Nigora Mukhamedova | |||
| Ying Fu | |||
| Jan M Orenstein | |||
| Tatiana Pushkarsky | |||
| Matthew P Morrow | |||
| Honor Rose | |||
| Larisa Dubrovsky | |||
| Zahedi Mujawar | |||
| P2860 | cites work | Endocytosis of major histocompatibility complex class I molecules is induced by the HIV–1 Nef protein | Q22251058 |
| Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. | Q50763481 | ||
| HIV-1 Nef-Induced Upregulation of DC-SIGN in Dendritic Cells Promotes Lymphocyte Clustering and Viral Spread | Q56795509 | ||
| HIV-1 Nef disrupts antigen presentation early in the secretory pathway | Q64379019 | ||
| Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B | Q70666068 | ||
| Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants | Q71903339 | ||
| Cell proliferation is not required for productive HIV-1 infection of macrophages | Q73435133 | ||
| Serine phosphorylation-independent downregulation of cell-surface CD4 by nef | Q22251290 | ||
| Apolipoprotein specificity for lipid efflux by the human ABCAI transporter | Q24290771 | ||
| Mechanism for down-regulation of CD28 by Nef. | Q24291079 | ||
| The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease | Q24306475 | ||
| Atherosclerosis | Q24644573 | ||
| Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes | Q28589822 | ||
| Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis | Q31643030 | ||
| Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? | Q33184007 | ||
| Abnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it? | Q33691904 | ||
| Tangier disease and ABCA1. | Q33927615 | ||
| Plasma membrane rafts play a critical role in HIV-1 assembly and release | Q33950207 | ||
| Microorganisms in the aetiology of atherosclerosis. | Q34065709 | ||
| ABCA1. The gatekeeper for eliminating excess tissue cholesterol. | Q34325121 | ||
| Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization | Q34348930 | ||
| Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: role of the acidic residue in the ExxxLL motif | Q34353332 | ||
| Do pathogens accelerate atherosclerosis? | Q34389205 | ||
| Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis | Q34443506 | ||
| Nef: agent of cell subversion | Q34552824 | ||
| Evidence for infectious agents in cardiovascular disease and atherosclerosis | Q34562273 | ||
| HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol | Q34648356 | ||
| Cardiovascular manifestations of HIV infection | Q34832031 | ||
| Consequences of altered isoprenylation targets on a-factor export and bioactivity | Q35038534 | ||
| Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions | Q35168397 | ||
| Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host | Q35753611 | ||
| Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes | Q35842465 | ||
| Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes | Q36354762 | ||
| Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages | Q36470857 | ||
| Foam cell formation inhibits growth of Chlamydia pneumoniae but does not attenuate Chlamydia pneumoniae-induced secretion of proinflammatory cytokines | Q37872007 | ||
| ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. Mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity | Q38363238 | ||
| HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages | Q39740926 | ||
| Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. | Q39880513 | ||
| A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes | Q40410574 | ||
| Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages | Q40497096 | ||
| Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I. | Q40516976 | ||
| Expression of caveolin-1 enhances cholesterol efflux in hepatic cells | Q40598222 | ||
| Crosstalk between LXR and Toll-like Receptor Signaling Mediates Bacterial and Viral Antagonism of Cholesterol Metabolism | Q40622775 | ||
| Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease | Q40677577 | ||
| Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. | Q40688664 | ||
| A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux | Q40757234 | ||
| Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. | Q40788372 | ||
| ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages | Q40864882 | ||
| Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. | Q40864887 | ||
| HIV-1 Reverse Transcription A Termination Step at the Center of the Genome | Q41443092 | ||
| Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium | Q41506795 | ||
| Cellular localization and trafficking of the human ABCA1 transporter | Q43604836 | ||
| Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction | Q43678570 | ||
| HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia | Q43811445 | ||
| Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages | Q43957626 | ||
| Structure-function studies of apoA-I variants: site-directed mutagenesis and natural mutations. | Q44102355 | ||
| Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome | Q44148482 | ||
| Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus | Q44177453 | ||
| Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? | Q44430812 | ||
| Coronary artery disease in HIV infected patients | Q44435381 | ||
| Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. | Q44460205 | ||
| Impact of HIV infection and HAART on serum lipids in men. | Q44473694 | ||
| Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort | Q44530878 | ||
| Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: part I. Differences due to the acquisition of HIV-infection | Q44545370 | ||
| Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). | Q44683564 | ||
| Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection | Q44801351 | ||
| ABCA1 expression in carotid atherosclerotic plaques. | Q45140725 | ||
| Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction | Q45486626 | ||
| Acute myocardial infarction in patients infected with human immunodeficiency virus | Q45702702 | ||
| Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. | Q45734592 | ||
| Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system | Q45746979 | ||
| Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection | Q45788093 | ||
| ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation | Q46265206 | ||
| Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions | Q47863833 | ||
| Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor | Q47950989 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| macrophage | Q184204 | ||
| P304 | page(s) | e365 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | PLOS Biology | Q1771695 |
| P1476 | title | Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. | |
| P478 | volume | 4 |
| Q41024442 | A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study. |
| Q35508301 | A prospective cohort study of periodontal disease measures and cardiovascular disease markers in HIV-infected adults |
| Q24316186 | ABCA12 regulates ABCA1-dependent cholesterol efflux from macrophages and the development of atherosclerosis |
| Q37339362 | Acute coronary syndrome in HIV patients: from pathophysiology to clinical practice |
| Q27008328 | Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy |
| Q37082957 | Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems. |
| Q43019131 | Alteration of lipid metabolism in cells infected with human cytomegalovirus |
| Q46350063 | Alterations in lipid transfer to high-density lipoprotein (HDL) and activity of paraoxonase-1 in HIV+ patients |
| Q36951647 | Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients. |
| Q30951038 | Alternative paths in HIV-1 targeted human signal transduction pathways |
| Q28393591 | An anti-inflammatory NOD-like receptor is required for microglia development |
| Q37376313 | Antiretroviral compounds and cholesterol efflux from macrophages |
| Q37584947 | Are reactive oxygen species always detrimental to pathogens? |
| Q38111810 | Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research |
| Q41934639 | Association of a 3' Untranslated Region Polymorphism in PCSK9 with HIV Viral Load and CD4+ Levels in HIV/Hepatitis C Virus Co-Infected Women |
| Q56919489 | Associations of gender and serum total cholesterol with CD4+ T cell count and HIV RNA load in antiretroviral-naïve individuals in Addis Ababa |
| Q34228996 | Atherogenic index of plasma in highly active antiretroviral therapy-naïve patients with human immunodeficiency virus infection in Southeast Nigeria |
| Q59357831 | Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection |
| Q30248286 | Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy |
| Q35203971 | Cardiovascular disease in HIV patients: from bench to bedside and backwards. |
| Q26777866 | Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk? |
| Q34793193 | Cardiovascular implications from untreated human immunodeficiency virus infection |
| Q38131061 | Cardiovascular involvements in HIV-infected patients |
| Q36367791 | Caveolin-1 reduces HIV-1 infectivity by restoration of HIV Nef mediated impairment of cholesterol efflux by apoA-I. |
| Q37156746 | Caveolin-1 suppresses human immunodeficiency virus-1 replication by inhibiting acetylation of NF-κB. |
| Q40556616 | Cdc42 - A tryst between host cholesterol metabolism and infection |
| Q38376511 | Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial |
| Q36286514 | Cholesterol efflux assay |
| Q58741972 | Cholesterol efflux responds to viral load and CD4 counts in HIV+ patients and is dampened in HIV exposed |
| Q38261556 | Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases |
| Q34101172 | Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux |
| Q38723259 | Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients |
| Q90436552 | Co-morbidities of HIV infection: role of Nef-induced impairment of cholesterol metabolism and lipid raft functionality |
| Q47866273 | Cocaine and HIV-1 Tat disrupt cholesterol homeostasis in astrocytes: Implications for HIV-associated neurocognitive disorders in cocaine user patients. |
| Q35101789 | Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial |
| Q34345729 | Constitutive gene expression in monocytes from chronic HIV-1 infection overlaps with acute Toll-like receptor induced monocyte activation profiles |
| Q35206635 | Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors |
| Q45395899 | Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study |
| Q52665460 | Could FDG-PET imaging play a role in the detection of progressing atherosclerosis in HIV-infected patients? |
| Q26852204 | Danger signaling in atherosclerosis |
| Q97550855 | Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection |
| Q24644759 | Deficiency of niemann-pick type C-1 protein impairs release of human immunodeficiency virus type 1 and results in Gag accumulation in late endosomal/lysosomal compartments |
| Q36691835 | Differences in the constitutive and SIV infection induced expression of Siglecs by hematopoietic cells from non-human primates |
| Q33264851 | Does HIV cause cardiovascular disease? |
| Q38823939 | Drug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization. |
| Q36102200 | Dynamic Association between HIV-1 Gag and Membrane Domains. |
| Q37039002 | Dynamics of lung macrophage activation in response to helminth infection. |
| Q35800393 | Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. |
| Q37319195 | Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection |
| Q92043736 | Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals |
| Q33608017 | Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients |
| Q34561360 | Effects of HIV-1-induced CD1c and CD1d modulation and endogenous lipid presentation on CD1c-restricted T-cell activation |
| Q39936190 | Effects of murine norovirus on atherosclerosis in ldlr(-/-) mice depends on the timing of infection |
| Q35338096 | Epidemiology and management of antiretroviral-associated cardiovascular disease |
| Q92173391 | Exosomes containing HIV protein Nef reorganize lipid rafts potentiating inflammatory response in bystander cells |
| Q38263962 | Frienemies of infection: A chronic case of host nuclear receptors acting as cohorts or combatants of infection |
| Q58798012 | From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection |
| Q90016199 | Greater IL-6, D-dimer, and ICAM-1 Levels Are Associated With Lower Small HDL Particle Concentration in the Multicenter AIDS Cohort Study |
| Q46224865 | HDL Cholesterol Efflux Capacity in Newly Diagnosed HIV and Effects of Antiretroviral Therapy |
| Q38293482 | HDL in infectious diseases and sepsis |
| Q33805298 | HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications |
| Q37485148 | HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells |
| Q42958246 | HIV and cardiovascular disease: contribution of HIV-infected macrophages to development of atherosclerosis |
| Q30239101 | HIV and its relationship to insulin resistance and lipid abnormalities. |
| Q64103636 | HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study |
| Q45357578 | HIV entry in macrophages is dependent on intact lipid rafts |
| Q36841647 | HIV infection and high density lipoprotein metabolism |
| Q35848134 | HIV inhibits endothelial reverse cholesterol transport through impacting subcellular Caveolin-1 trafficking |
| Q35576175 | HIV is an independent predictor of aortic stiffness |
| Q33775135 | HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis |
| Q33361587 | HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study |
| Q36531107 | HIV-1 Nef in macrophage-mediated disease pathogenesis. |
| Q35184027 | HIV-1 Nef is transferred from expressing T cells to hepatocytic cells through conduits and enhances HCV replication |
| Q35839673 | HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux |
| Q35068359 | HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells |
| Q55967625 | HIV-1 and the macrophage |
| Q37726306 | HIV-1 assembly in macrophages |
| Q41749565 | HIV-1 infection of macrophages induces retention of cholesterol transporter ABCA1 in the endoplasmic reticulum |
| Q34355599 | HIV-1 protein Nef inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexin |
| Q37018213 | HIV-associated dyslipidaemia: pathogenesis and treatment |
| Q43155426 | HIV-related cardiovascular risk factors |
| Q38013681 | HIV-specific immune dysregulation and atherosclerosis |
| Q33556997 | High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection |
| Q31127155 | High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort |
| Q35072075 | High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection |
| Q37455285 | Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells |
| Q91638984 | How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy |
| Q36512300 | Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease |
| Q35104006 | Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease |
| Q37337364 | Human immunodeficiency virus downregulates podocyte apoE expression |
| Q39779756 | Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains |
| Q37639821 | Human paraoxonase-1 activity is related to the number of CD4+ T-cells and is restored by antiretroviral therapy in HIV-1-infected individuals |
| Q58599380 | Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from Monocytes: Possible Implications for Suppression of HIV Chronic Immune Activation |
| Q34673075 | Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients |
| Q55515189 | Impact of Dietary Cholesterol on the Pathophysiology of Infectious and Autoimmune Disease. |
| Q35850911 | Impact of cholesterol on disease progression |
| Q34512603 | Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function. |
| Q37709593 | Implications for lipids during replication of enveloped viruses |
| Q37169956 | Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon |
| Q37195784 | Infectious and Non-infectious Etiologies of Cardiovascular Disease in Human Immunodeficiency Virus Infection |
| Q35873877 | Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. |
| Q36957752 | Inflammation, immune activation, and cardiovascular disease in HIV. |
| Q38370895 | Inflammation-induced foam cell formation in chronic inflammatory disease. |
| Q26851535 | Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus |
| Q92822217 | Inhibition of HIV Replication by Apolipoprotein A-I Binding Protein Targeting the Lipid Rafts |
| Q58763014 | Insulin Resistance in HIV-Patients: Causes and Consequences |
| Q36089178 | Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation. |
| Q34451471 | Interaction of pathogens with host cholesterol metabolism |
| Q37435125 | Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy |
| Q36421895 | Lipid metabolism in patients infected with Nef-deficient HIV-1 strain |
| Q39293001 | Lipid testing in infectious diseases: possible role in diagnosis and prognosis |
| Q27489393 | Lipids and membrane microdomains in HIV-1 replication |
| Q42602737 | Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection |
| Q21245090 | Loss of Niemann Pick type C proteins 1 and 2 greatly enhances HIV infectivity and is associated with accumulation of HIV Gag and cholesterol in late endosomes/lysosomes |
| Q34028922 | Low cholesterol? Don't brag yet ... hypocholesterolemia blunts HAART effectiveness: a longitudinal study |
| Q64067626 | Macrophage nuclear receptors: Emerging key players in infectious diseases |
| Q35643573 | Management of dyslipidemia in HIV-infected patients |
| Q33330313 | Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk |
| Q59357001 | Modelling interaction between HIV-1 Nef and calnexin |
| Q39577894 | Modulation of HIV pathogenesis and T-cell signaling by HIV-1 Nef |
| Q27006827 | Monocytes as regulators of inflammation and HIV-related comorbidities during cART |
| Q37378957 | Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration |
| Q47555946 | Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature |
| Q36197571 | Murine Norovirus Infection Variably Alters Atherosclerosis in Mice Lacking Apolipoprotein E |
| Q34146122 | Mutation of the ATP Cassette Binding Transporter A1 (ABCA1) C-Terminus Disrupts HIV-1 Nef Binding but Does Not Block the Nef Enhancement of ABCA1 Protein Degradation |
| Q35239866 | Myeloid-specific estrogen receptor alpha deficiency impairs metabolic homeostasis and accelerates atherosclerotic lesion development |
| Q37043004 | Nature, nurture and HIV: The effect of producer cell on viral physiology |
| Q36949578 | Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles |
| Q33751856 | New clues to understanding HIV nonprogressors: low cholesterol blocks HIV trans infection |
| Q35274791 | Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms |
| Q35970578 | Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial |
| Q37038775 | Pathophysiology and management of cardiovascular disease in patients with HIV |
| Q43155421 | Physiopathology of cardiovascular disease in HIV-infected patients |
| Q35120957 | Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART |
| Q36949766 | Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides. |
| Q38261508 | Risk of coronary heart disease in patients with HIV infection |
| Q30457521 | Risk stratification and prognosis of human immunodeficiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography |
| Q39930180 | Ritonavir increases CD36, ABCA1 and CYP27 expression in THP-1 macrophages |
| Q38227871 | Role of Gag and lipids during HIV-1 assembly in CD4(+) T cells and macrophages. |
| Q41894655 | Role of MyD88-dependent and MyD88-independent signaling in Porphyromonas gingivalis-elicited macrophage foam cell formation. |
| Q40835741 | Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense. |
| Q28506217 | SPTLC1 binds ABCA1 to negatively regulate trafficking and cholesterol efflux activity of the transporter |
| Q40533665 | Short Communication: Accumulation of Neutral Lipids in Liver and Aorta of Nef-Transgenic Mice |
| Q38334892 | Sterol regulatory element-binding protein 2 couples HIV-1 transcription to cholesterol homeostasis and T cell activation |
| Q35962036 | Stimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection |
| Q34051644 | Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1 |
| Q36359313 | TARGETING OF MACROPHAGE FOAM CELLS IN ATHEROSCLEROTIC PLAQUE USING OLIGONUCLEOTIDE-FUNCTIONALIZED NANOPARTICLES |
| Q39097984 | The ABCA1 domain responsible for interaction with HIV-1 Nef is conformational and not linear |
| Q91811483 | The HIV Reservoir in Monocytes and Macrophages |
| Q28730200 | The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes |
| Q38760883 | The LXR ligand GW3965 inhibits Newcastle disease virus infection by affecting cholesterol homeostasis |
| Q37959034 | The Nef-infectivity enigma: mechanisms of enhanced lentiviral infection |
| Q32183747 | The Role of Caveolin 1 in HIV Infection and Pathogenesis |
| Q34080779 | The Role of Lipids in Retrovirus Replication |
| Q33889580 | The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms |
| Q36951676 | The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study. |
| Q44482690 | The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation. |
| Q34898069 | The macrophage: the intersection between HIV infection and atherosclerosis. |
| Q28386344 | The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction |
| Q27021950 | The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism |
| Q34137493 | The scaffolding protein Dlg1 is a negative regulator of cell-free virus infectivity but not of cell-to-cell HIV-1 transmission in T cells |
| Q42030451 | Transcriptome analysis of monocyte-HIV interactions |
| Q37756963 | Treatment of dyslipidemia in HIV-infected patients |
| Q38363531 | Treatment of dyslipidemia in HIV. |
| Q36980757 | Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration |
| Q41754765 | Vimentin-a potential biomarker for therapeutic efficiency of HAART. |
| Q34015853 | Virus vasculopathy and stroke: an under-recognized cause and treatment target |
| Q52398755 | [Controversies and future of the approach to cardiovascular disease in HIV patients]. |
Search more.